Intranasal vs. IV Dexmedetomidine in Endoscopic Sinus Surgery

Launched by KAFRELSHEIKH UNIVERSITY · Oct 22, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at two different ways to give a medication called dexmedetomidine during Functional Endoscopic Sinus Surgery (FESS). The researchers want to see if giving dexmedetomidine through the nose (intranasal) is just as effective as giving it through an IV (intravenous) in keeping the surgical area clear and making the surgery smoother. The trial is currently recruiting participants aged 18 and older, regardless of gender, who are in good health (classified as ASA I or II) and scheduled for this type of sinus surgery.

If you or someone you know is interested in participating, it's important to note that certain health conditions may exclude someone from the study. For example, individuals with a high body weight (BMI over 30), significant heart problems, or a history of drug allergies may not be eligible. Participants will receive either the intranasal or IV dexmedetomidine during their surgery and will help researchers determine which method is better for improving surgical conditions. This trial could provide valuable information about how to enhance care for patients undergoing sinus surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients older than 18 years of age
• • Both genders
• • American Society of Anesthesiologists (ASA) physical status classification I or II
• • Undergoing Functional Endoscopic Sinus Surgery.
• Exclusion Criteria:
• • Patients with a body mass index \> 30 kg/m\^2
• • contraindications to the use of dexmedetomidine
• • history or presence of a significant disease
• • significant cardiovascular disease risk factors
• • significant coronary artery disease or any known genetic predisposition
• • history of any kind of drug allergy
• • drug abuse
• • psychological or other emotional problems
• • special diet or lifestyle
• • clinically significant abnormal findings in physical examination
• • electrocardiographic (ECG) or laboratory screening
• • known systemic disease requiring the use of anticoagulants
• • patients with a history of previous Functional Endoscopic Sinus Surgery.